These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 23243925)
1. [The harmfulness of drugs and slimming substances--a toxicologist's point of view]. Kujawa A; Szponar J; Szponar E; Zapalska-Pozarowska K; Kostek H Przegl Lek; 2012; 69(8):548-51. PubMed ID: 23243925 [TBL] [Abstract][Full Text] [Related]
2. [Pharmacological therapy of obesity]. Pagotto U; Vanuzzo D; Vicennati V; Pasquali R G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755 [TBL] [Abstract][Full Text] [Related]
3. Drug strategies for the treatment of obesity. Alemany M; Remesar X; Fernández-López JA IDrugs; 2003 Jun; 6(6):566-72. PubMed ID: 12811679 [TBL] [Abstract][Full Text] [Related]
4. Pharmacotherapy for obesity. Lee PC; Dixon J Aust Fam Physician; 2017; 46(7):472-477. PubMed ID: 28697290 [TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy for obesity. Li M; Cheung BM Br J Clin Pharmacol; 2009 Dec; 68(6):804-10. PubMed ID: 20002075 [TBL] [Abstract][Full Text] [Related]
6. Drug treatment of obesity. Bray GA Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Apr; 13(1):131-48. PubMed ID: 10932681 [TBL] [Abstract][Full Text] [Related]
8. [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine]. Richter WO MMW Fortschr Med; 1999 Dec; 141(49-50):32-6. PubMed ID: 10726144 [TBL] [Abstract][Full Text] [Related]
9. [The "problem obesity": viewpoint of the internist]. Guagnano MT; Manigrasso MR; Capani F; Davì G Ann Ital Chir; 2005; 76(5):407-11. PubMed ID: 16696212 [TBL] [Abstract][Full Text] [Related]
10. Long-term pharmacotherapy for obesity. Klein S Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412 [TBL] [Abstract][Full Text] [Related]
11. Slim spoils for obesity drugs. Ledford H Nature; 2010 Dec; 468(7326):878. PubMed ID: 21164452 [No Abstract] [Full Text] [Related]
12. Pharmacological approaches for the treatment of obesity. Fernández-López JA; Remesar X; Foz M; Alemany M Drugs; 2002; 62(6):915-44. PubMed ID: 11929339 [TBL] [Abstract][Full Text] [Related]
13. Anti-obesity drugs: use, mechanisms and clinical importance. Adam O; Forth W Int J Clin Pharmacol Ther; 2001 Jun; 39(6):232-8. PubMed ID: 11430630 [TBL] [Abstract][Full Text] [Related]
15. Orlistat--a novel weight loss therapy. Lucas KH; Kaplan-Machlis B Ann Pharmacother; 2001 Mar; 35(3):314-28. PubMed ID: 11261530 [TBL] [Abstract][Full Text] [Related]
16. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247 [TBL] [Abstract][Full Text] [Related]
17. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents. García Díaz E; Martín Folgueras T Nutr Hosp; 2011; 26(3):451-7. PubMed ID: 21892560 [TBL] [Abstract][Full Text] [Related]
18. [The pharmacotherapy of obesity]. Budai KA; Mirzahosseini A; Noszál Béla ; Tóth G Acta Pharm Hung; 2015; 85(1):3-17. PubMed ID: 26137782 [TBL] [Abstract][Full Text] [Related]